What are the recommendations for REMS when prescribing Qsymia?

The recommendation to conduct a pregnancy test before starting Qsymia and monthly thereafter is based on the medication's potential risks during pregnancy. Qsymia contains phentermine and topiramate, both of which can pose significant risks to fetal development if taken during pregnancy. The monthly testing ensures that any potential pregnancy is identified early, allowing for timely intervention if a patient becomes pregnant while on the medication. This practice helps mitigate risks and aligns with the REMS (Risk Evaluation and Mitigation Strategy) requirements aimed at protecting patients who may be of childbearing potential.

Implementing this precaution emphasizes the importance of safe prescribing practices and patient monitoring, particularly in populations that may be at risk for unintended pregnancy. Regular pregnancy testing provides a safeguard for both the healthcare provider and the patient, ensuring that the benefits of Qsymia can be taken without significant harm to a developing fetus.